Comparison Between Quadruple Regimens for Helicobacter Pylori Infection in Egypt

• Status: Completed
• Trial end date: 2019-06-30
• Target enrollment: 0
• Participant gender: All

Summary

The overall prevalence of H. Pylori in the developing countries is 50.8%, with the highest one presented in Africa (79.1%). Hybrid therapy is supposed to be more effective as a first-line regimen for Helicobacter pylori infection in Egypt than the Reverse hybrid and non-bismuth Levofloxacin quadruple therapies. We are aiming here to compare the Hybrid, Reverse hybrid, and Levofloxacin quadruple therapies as first-line therapy, trying to reach the safest, cost-effective, and compliance-inducing regimen in Egypt. We will conduct a randomized controlled (interventional) study at Zagazig University Hospital, internal medicine department clinic, on 330 patients. 110 patients will be allocated to each regimen.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ayman Magd Eldin Mohammad Sadek
• Treatments: Levofloxacin; Ofloxacin

Criteria

Inclusion Criteria:

• Positive Helicobacter pylori antigen in the stool

• Treatment-naive

Exclusion Criteria:

• Previous treatment for Helicobacter pylori

• Drug hypersensitivity